Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for Cognitive Impairment After Ischemic Stroke
NCT06344390Phase 2Recruiting
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- Apr 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pentoxifylline in post-stroke cognitive impairment (PSCI) (2 arms), sponsored by The First Hospital of Hebei Medical University. Primary endpoint: Improvement of cognitive impairment after ischemic stroke at 3 months. Started Apr 2024; status: recruiting.
02
Drugs
pentoxifylline
03
Conditions
post-stroke cognitive impairment (PSCI)
Beyond the preview
Go deeper on NCT06344390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344390.